About Lupin
Lupin is a company based in Mumbai (India) founded in 1968. The company has 26,210 employees as of March 31, 2024. Lupin has completed 11 acquisitions, including Biocom, Biocom California and Harmosan Pharma.
- Headquarter Mumbai, India
- Employees 26210 as on 31 Mar, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Lupin Limited
-
Annual Revenue
$2.6 B (USD)12.84as on Mar 31, 2025
-
Net Profit
$384.16 M (USD)71.41as on Mar 31, 2025
-
EBITDA
$570.38 M (USD)37.31as on Mar 31, 2025
-
Latest Funding Round
$25 M (USD), Post-IPO
Jun 29, 2023
-
Investors
AbbVie
& 2 more
-
Employee Count
26210
as on Mar 31, 2024
-
Investments & Acquisitions
Biocom
& 10 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Lupin
Lupin is a publicly listed company on the NSE with ticker symbol LUPIN in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
People of Lupin
Unlock access to complete
Unlock access to complete
Software Development Team
99 people
Leadership Team
54 people
Human Resources and Administration
35 people
Sales and Marketing
29 people
Finance and Accounting
22 people
Senior Team
17 people
Product Management Team
16 people
Manager Team
10 people
Unlock access to complete
Funding Insights of Lupin
Investors in Lupin
Lupin has secured backing from 3 investors, including institutional investors. Prominent investors backing the company include AbbVie, Boehringer Ingelheim and National Science Foundation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Biopharmaceutical research and drug development are conducted globally by AbbVie.
|
Locked | Locked | Locked | |
|
Generic drugs and clinical research services are provided globally.
|
Locked | Locked | Locked | |
|
A government-backed foundation providing seed-stage investments to support small businesses.
|
Locked | Locked | Locked |
Investor details for Lupin
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Lupin
Lupin has strategically engaged in corporate development activities, having acquired 11 companies. Notable acquisitions include Biocom, Biocom California and Harmosan Pharma.
Investment portfolio details for Lupin
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Ophthalmic medicine products are manufactured by VISUfarma in Amsterdam.
|
Locked | Locked | 2016 | Locked | |
|
Late-stage biopharma antibiotics for gynecological infections are developed.
|
Locked | Locked | 2012 | Locked | |
|
Sustained release injectables are developed and manufactured using Monosphere Technology.
|
Locked | Locked | 2004 | Locked |
Complete acquisition details for Lupin
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Lupin
Detailed financials for Lupin
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Lupin Comparisons
Peer comparison for Lupin
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Lupin
Detailed competitors of Lupin
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Lupin
Complete news archive for Lupin
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Lupin
Lupin was founded in 1968 and raised its 1st funding round 45 years after it was founded.
Lupin is headquartered in Mumbai, India. It is registered at Mumbai, Maharashtra, India.
Vinita D Gupta is the current CEO of Lupin.
As of Mar 31, 2024, the latest employee count at Lupin is 26,210.
Annual revenue of Lupin is $2.6B as on Mar 31, 2025.
Lupin was founded in 1968 in Mumbai, India, within the pharmaceutical sector. Generics, biosimilars, and active pharmaceutical ingredients are produced, alongside offerings in key therapeutic areas. Tech-driven solutions, over-the-counter medications, biotech products, and contract development and manufacturing organization services are provided. A global institutional business is operated, with manufacturing solutions extended internationally. Research and development efforts are directed toward advancing industry standing.
Yes, Lupin is publicly traded on NSE under the ticker symbol LUPIN.
Lupin has made 11 acquisitions, including Biocom, Biocom California, and Harmosan Pharma.
Lupin has 3 investors. Key investors include AbbVie, Boehringer Ingelheim, and National Science Foundation.
The ticker symbol of Lupin is LUPIN on NSE.